从“最小”介入器械到智能影像设备，进博会构建全球资源与中国智慧新“秀场”｜聚焦2025进博会

Core Insights - The ongoing 8th China International Import Expo (CIIE) highlights the increasing "health value" of the event, showcasing cutting-edge medical technologies from global leaders in the healthcare sector [2][8] - Major multinational companies are deepening their investment in China, viewing it as a significant opportunity for innovation and market growth, particularly in the healthcare sector [8][9] Medical Technology Innovations - Sonova introduced the world's first AI chip for hearing aids, emphasizing the importance of hearing health in the changing social and demographic landscape [2] - Medtronic's Inceptiv, a closed-loop rechargeable spinal cord stimulator, can automatically adjust stimulation based on real-time biological signals, enhancing patient comfort and quality of life [3] - The introduction of advanced solutions in precision radiotherapy by Meikeda, including the first clinical research white paper on high-field MRI-guided adaptive radiotherapy in China [5] - Siemens showcased a comprehensive brain-machine interface solution that enhances surgical precision and safety, reflecting the integration of digitalization and AI in healthcare [5][12] Pharmaceutical Developments - Johnson & Johnson presented breakthrough solutions for cardiovascular diseases, including the FDA-approved Impella® CP with SmartAssist device, which improves survival rates for patients in cardiogenic shock [7] - Omron Health's smart health management solutions address chronic disease management, focusing on early risk screening and continuous monitoring [7] - Novartis highlighted its commitment to the Chinese market with significant investments and the introduction of innovative products, including a radioactive drug production base in Zhejiang [9][10] Market Dynamics and Opportunities - The CIIE serves as a crucial platform for foreign companies to establish and deepen their presence in the Chinese market, aligning with the "Healthy China 2030" strategy [8][9] - The total amount of foreign licensing for innovative drugs from China has surpassed $100 billion, indicating the growing strength of China's pharmaceutical innovation [11] - The introduction of innovative treatments at the CIIE is accelerating access to advanced medical solutions for Chinese patients, exemplified by the rapid approval and integration of new drugs into the national healthcare system [11][12]